vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $12.1M, roughly 1.8× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs 7.2%, a 61.5% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 2.3%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 0.7%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
CUE vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $12.1M |
| Net Profit | $1.6M | $8.3M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | -28.9% |
| Net Margin | 7.2% | 68.8% |
| Revenue YoY | 1292.3% | 2.3% |
| Net Profit YoY | 116.7% | 7577.8% |
| EPS (diluted) | $0.05 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $12.1M | ||
| Q3 25 | $2.1M | $12.8M | ||
| Q2 25 | $3.0M | $12.2M | ||
| Q1 25 | $421.0K | $12.0M | ||
| Q4 24 | $1.6M | $11.8M | ||
| Q3 24 | $3.3M | $11.6M | ||
| Q2 24 | $2.7M | $11.8M | ||
| Q1 24 | $1.7M | $11.9M |
| Q4 25 | $1.6M | $8.3M | ||
| Q3 25 | $-7.4M | $724.0K | ||
| Q2 25 | $-8.5M | $169.0K | ||
| Q1 25 | $-12.3M | $4.6M | ||
| Q4 24 | — | $108.0K | ||
| Q3 24 | $-8.7M | $1.7M | ||
| Q2 24 | $-10.2M | $1.5M | ||
| Q1 24 | $-12.3M | $2.5M |
| Q4 25 | 9.0% | -28.9% | ||
| Q3 25 | -353.4% | -10.9% | ||
| Q2 25 | -292.3% | -6.8% | ||
| Q1 25 | -2921.4% | -5.3% | ||
| Q4 24 | — | -14.3% | ||
| Q3 24 | -264.2% | -14.4% | ||
| Q2 24 | -390.6% | -9.2% | ||
| Q1 24 | -737.8% | -11.2% |
| Q4 25 | 7.2% | 68.8% | ||
| Q3 25 | -346.6% | 5.6% | ||
| Q2 25 | -287.1% | 1.4% | ||
| Q1 25 | -2911.4% | 38.5% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | -259.6% | 14.7% | ||
| Q2 24 | -382.7% | 12.7% | ||
| Q1 24 | -719.1% | 21.4% |
| Q4 25 | $0.05 | $0.97 | ||
| Q3 25 | $-0.07 | $0.08 | ||
| Q2 25 | $-0.09 | $0.02 | ||
| Q1 25 | $-0.17 | $0.53 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.17 | $0.20 | ||
| Q2 24 | $-0.20 | $0.17 | ||
| Q1 24 | $-0.25 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $26.4M | $846.7M |
| Total Assets | $42.2M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $89.0M | ||
| Q3 25 | $11.7M | $82.7M | ||
| Q2 25 | $27.5M | $73.5M | ||
| Q1 25 | $13.1M | $88.6M | ||
| Q4 24 | $22.5M | $99.7M | ||
| Q3 24 | $32.4M | $131.6M | ||
| Q2 24 | $30.0M | $127.5M | ||
| Q1 24 | $41.0M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | $1.0M | $180.3M | ||
| Q2 24 | $2.0M | $177.4M | ||
| Q1 24 | $3.0M | $178.3M |
| Q4 25 | $26.4M | $846.7M | ||
| Q3 25 | $13.2M | $838.4M | ||
| Q2 25 | $18.2M | $837.7M | ||
| Q1 25 | $6.6M | $837.3M | ||
| Q4 24 | $17.5M | $832.3M | ||
| Q3 24 | $25.4M | $832.2M | ||
| Q2 24 | $21.6M | $830.4M | ||
| Q1 24 | $30.0M | $828.9M |
| Q4 25 | $42.2M | $1.1B | ||
| Q3 25 | $31.6M | $1.1B | ||
| Q2 25 | $40.7M | $1.1B | ||
| Q1 25 | $22.3M | $1.1B | ||
| Q4 24 | $32.2M | $1.1B | ||
| Q3 24 | $44.8M | $1.1B | ||
| Q2 24 | $42.3M | $1.0B | ||
| Q1 24 | $54.0M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | 0.04× | 0.22× | ||
| Q2 24 | 0.09× | 0.21× | ||
| Q1 24 | 0.10× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-2.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -0.68× | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-2.9M | ||
| Q3 25 | $-9.0M | $8.2M | ||
| Q2 25 | $-3.4M | $-2.9M | ||
| Q1 25 | $-8.2M | $-7.4M | ||
| Q4 24 | $-36.3M | $1.3M | ||
| Q3 24 | $-7.5M | $13.7M | ||
| Q2 24 | $-10.0M | $-511.0K | ||
| Q1 24 | $-9.8M | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-9.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | — | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | — | ||
| Q2 24 | -376.2% | — | ||
| Q1 24 | -573.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | -0.68× | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
TCI
Segment breakdown not available.
